CAMP4 Therapeutics Corporation - Common Stock (CAMP)

CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company’s common stock to three newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model

Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026 

Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human cells

Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026

CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on February 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST.

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gross proceeds to the Company from this offering are expected to be $30.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases

CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 92,000 shares of the Company’s common stock to four newly hired employees of the Company, each as an inducement material to each employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on November 12, 2025 (the “Grant Date”), the Company’s Board of Directors granted a non-qualified stock option to purchase 80,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders 

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the initiation of toxicology studies conducted under Good Laboratory Practice (GLP) standards for its lead product candidate, CMP-SYNGAP-01. These studies will support the Company’s planned submission of a clinical trial application, which could enable the initiation of a first-in-human Phase 1/2 clinical trial in SYNGAP1-related disorders as early as the second half of 2026.